The Future of Diabetes Care: Unlocking the Potential of Continuous Ketone Monitoring
Diabetic ketoacidosis (DKA) is a serious and potentially fatal condition that demands our attention. But here's where it gets controversial: despite its severity, DKA is often preventable. So, why are we still seeing high rates of DKA in people with Type 1 Diabetes (T1D)?
The answer may lie in the limitations of current monitoring methods. Traditional blood and urine tests for ketones are not always effective in predicting DKA, and many people with T1D don't regularly monitor their ketone levels. This is where continuous ketone monitoring (CKM) steps in, promising to revolutionize diabetes care.
A groundbreaking paper, published in The Lancet Diabetes & Endocrinology, offers international expert recommendations on CKM. Led by Thomas Danne, M.D., Ph.D., the study highlights the potential of CKM to transform T1D management. CKM devices, similar to continuous glucose monitors (CGMs), will provide real-time ketone level tracking, alerting users to potential DKA risks.
And this is the part most people miss: CKM can benefit a wide range of individuals with T1D. From insulin pump users at higher DKA risk due to potential infusion issues, to pregnant women with diabetes who may have increased insulin resistance, CKM offers a tailored solution.
The paper provides a comprehensive snapshot of CKM recommendations, including:
- Implementing trend arrows to indicate ketone level changes, similar to CGMs.
- Setting alarms for ketone concentration thresholds to combat alarm fatigue.
- Standardizing ketone level terminology for better communication.
- Providing blood ketone meters and education to all CKM users.
These guidelines are crucial for healthcare professionals and people with T1D to maximize the benefits of CKM. By standardizing CKM integration into clinics, we can ensure that this technology becomes a valuable tool in diabetes management, potentially reducing DKA rates and improving patient outcomes.
But there's a catch: CKM devices are still in development. Companies like Abbott are working on glucose-ketone sensors, while others plan to integrate these sensors into their automated insulin delivery systems. Breakthrough T1D is actively supporting CKM research, funding projects to accelerate evidence generation and clinical understanding.
As we eagerly await the arrival of CKM, we must prepare the T1D community and healthcare professionals for this innovative technology. By doing so, we can ensure a smooth clinical adoption process and unlock the full potential of CKM in preventing DKA and enhancing diabetes care.
Are you ready to embrace the future of diabetes management? CKM is coming, and it's time to get prepared!
